

David D Ho

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7959940/publications.pdf>

Version: 2024-02-01

61
papers

22,719
citations

94269

37
h-index

128067

60
g-index

92
all docs

92
docs citations

92
times ranked

24104
citing authors

#	ARTICLE	IF	CITATIONS
1	Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. <i>Nature</i> , 1995, 373, 123-126.	13.7	4,277
2	Extrapulmonary manifestations of COVID-19. <i>Nature Medicine</i> , 2020, 26, 1017-1032.	15.2	2,300
3	Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7. <i>Nature</i> , 2021, 593, 130-135.	13.7	1,904
4	Decay characteristics of HIV-1-infected compartments during combination therapy. <i>Nature</i> , 1997, 387, 188-191.	13.7	1,722
5	Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike. <i>Nature</i> , 2020, 584, 450-456.	13.7	1,337
6	Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody. <i>Science</i> , 1994, 266, 1024-1027.	6.0	1,080
7	Sequence and Structural Convergence of Broad and Potent HIV Antibodies That Mimic CD4 Binding. <i>Science</i> , 2011, 333, 1633-1637.	6.0	1,046
8	Striking antibody evasion manifested by the Omicron variant of SARS-CoV-2. <i>Nature</i> , 2022, 602, 676-681.	13.7	1,038
9	Antibody evasion properties of SARS-CoV-2 Omicron sublineages. <i>Nature</i> , 2022, 604, 553-556.	13.7	649
10	A Human Pluripotent Stem Cell-based Platform to Study SARS-CoV-2 Tropism and Model Virus Infection in Human Cells and Organoids. <i>Cell Stem Cell</i> , 2020, 27, 125-136.e7.	5.2	543
11	Antibody evasion by SARS-CoV-2 Omicron subvariants BA.2.12.1, BA.4 and BA.5. <i>Nature</i> , 2022, 608, 603-608.	13.7	541
12	Increased resistance of SARS-CoV-2 variant P.1 to antibody neutralization. <i>Cell Host and Microbe</i> , 2021, 29, 747-751.e4.	5.1	504
13	Rapid production and clearance of HIV-1 and hepatitis C virus assessed by large volume plasma apheresis. <i>Lancet, The</i> , 1999, 354, 1782-1785.	6.3	458
14	Potent SARS-CoV-2 neutralizing antibodies directed against spike N-terminal domain target a single super-site. <i>Cell Host and Microbe</i> , 2021, 29, 819-833.e7.	5.1	444
15	Identification of SARS-CoV-2 inhibitors using lung and colonic organoids. <i>Nature</i> , 2021, 589, 270-275.	13.7	389
16	A Novel Antiviral Intervention Results in More Accurate Assessment of Human Immunodeficiency Virus Type 1 Replication Dynamics and T-Cell Decay In Vivo. <i>Journal of Virology</i> , 2003, 77, 5037-5038.	1.5	356
17	Cryo-EM Structures of SARS-CoV-2 Spike without and with ACE2 Reveal a pH-Dependent Switch to Mediate Endosomal Positioning of Receptor-Binding Domains. <i>Cell Host and Microbe</i> , 2020, 28, 867-879.e5.	5.1	316
18	Defining variant-resistant epitopes targeted by SARS-CoV-2 antibodies: A global consortium study. <i>Science</i> , 2021, 374, 472-478.	6.0	228

#	ARTICLE	IF	CITATIONS
19	Engineered Bispecific Antibodies with Exquisite HIV-1-Neutralizing Activity. <i>Cell</i> , 2016, 165, 1621-1631.	13.5	157
20	Nanobodies from camelid mice and llamas neutralize SARS-CoV-2 variants. <i>Nature</i> , 2021, 595, 278-282.	13.7	154
21	Real-Time Conformational Dynamics of SARS-CoV-2 Spikes on Virus Particles. <i>Cell Host and Microbe</i> , 2020, 28, 880-891.e8.	5.1	153
22	Long-Acting Integrase Inhibitor Protects Macaques from Intrarectal Simian/Human Immunodeficiency Virus. <i>Science</i> , 2014, 343, 1151-1154.	6.0	145
23	Viral dynamics of acute SARS-CoV-2 infection and applications to diagnostic and public health strategies. <i>PLoS Biology</i> , 2021, 19, e3001333.	2.6	133
24	Defining the risk of SARS-CoV-2 variants on immune protection. <i>Nature</i> , 2022, 605, 640-652.	13.7	117
25	SARS-CoV-2 neutralizing antibody responses are more robust in patients with severe disease. <i>Emerging Microbes and Infections</i> , 2020, 9, 2091-2093.	3.0	109
26	In vivo kinetics of SARS-CoV-2 infection and its relationship with a person's infectiousness. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	3.3	108
27	Emergence and expansion of SARS-CoV-2 B.1.526 after identification in New York. <i>Nature</i> , 2021, 597, 703-708.	13.7	103
28	Robust SARS-CoV-2 infection in nasal turbinates after treatment with systemic neutralizing antibodies. <i>Cell Host and Microbe</i> , 2021, 29, 551-563.e5.	5.1	87
29	Cryo-EM structure of the SARS-CoV-2 Omicron spike. <i>Cell Reports</i> , 2022, 38, 110428.	2.9	82
30	Bispecific antibodies directed to CD4 domain 2 and HIV envelope exhibit exceptional breadth and picomolar potency against HIV-1. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, 13540-13545.	3.3	73
31	A SARS-CoV-2 ferritin nanoparticle vaccine elicits protective immune responses in nonhuman primates. <i>Science Translational Medicine</i> , 2022, 14, .	5.8	73
32	Striking antibody evasion manifested by the Omicron variant of SARS-CoV-2. <i>Nature</i> , 0, , .	13.7	72
33	Shutting down HIV. <i>Nature</i> , 1994, 370, 416-416.	13.7	70
34	Lead compounds for the development of SARS-CoV-2 3CL protease inhibitors. <i>Nature Communications</i> , 2021, 12, 2016.	5.8	65
35	Structure-Based Design with Tag-Based Purification and In-Process Biotinylation Enable Streamlined Development of SARS-CoV-2 Spike Molecular Probes. <i>Cell Reports</i> , 2020, 33, 108322.	2.9	59
36	Modular basis for potent SARS-CoV-2 neutralization by a prevalent VH1-2-derived antibody class. <i>Cell Reports</i> , 2021, 35, 108950.	2.9	54

#	ARTICLE	IF	CITATIONS
37	Structural basis for accommodation of emerging B.1.351 and B.1.1.7 variants by two potent SARS-CoV-2 neutralizing antibodies. <i>Structure</i> , 2021, 29, 655-663.e4.	1.6	52
38	Neutralizing antibody 5-7 defines a distinct site of vulnerability in SARS-CoV-2 spike N-terminal domain. <i>Cell Reports</i> , 2021, 37, 109928.	2.9	52
39	SARS-CoV-2 Infection Induces Ferroptosis of Sinoatrial Node Pacemaker Cells. <i>Circulation Research</i> , 2022, 130, 963-977.	2.0	49
40	Development of optimized drug-like small molecule inhibitors of the SARS-CoV-2 3CL protease for treatment of COVID-19. <i>Nature Communications</i> , 2022, 13, 1891.	5.8	45
41	Quantifying the contribution of Fc-mediated effector functions to the antiviral activity of anti-HIV-1 IgG1 antibodies in vivo. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 18002-18009.	3.3	44
42	Efficacy and breadth of adjuvanted SARS-CoV-2 receptor-binding domain nanoparticle vaccine in macaques. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	3.3	44
43	An Immuno-Cardiac Model for Macrophage-Mediated Inflammation in COVID-19 Hearts. <i>Circulation Research</i> , 2021, 129, 33-46.	2.0	40
44	Paired heavy- and light-chain signatures contribute to potent SARS-CoV-2 neutralization in public antibody responses. <i>Cell Reports</i> , 2021, 37, 109771.	2.9	38
45	Engineering multi-specific antibodies against HIV-1. <i>Retrovirology</i> , 2018, 15, 60.	0.9	37
46	Cardiomyocytes recruit monocytes upon SARS-CoV-2 infection by secreting CCL2. <i>Stem Cell Reports</i> , 2021, 16, 2274-2288.	2.3	37
47	An airway organoid-based screen identifies a role for the HIF1 α -glycolysis axis in SARS-CoV-2 infection. <i>Cell Reports</i> , 2021, 37, 109920.	2.9	36
48	An antibody class with a common CDRH3 motif broadly neutralizes sarbecoviruses. <i>Science Translational Medicine</i> , 2022, 14, eabn6859.	5.8	31
49	CRISPR-based gene knockout screens reveal deubiquitinases involved in HIV-1 latency in two Jurkat cell models. <i>Scientific Reports</i> , 2020, 10, 5350.	1.6	30
50	Inhibitors of Coronavirus 3CL Proteases Protect Cells from Protease-Mediated Cytotoxicity. <i>Journal of Virology</i> , 2021, 95, e0237420.	1.5	27
51	A monoclonal antibody that neutralizes SARS-CoV-2 variants, SARS-CoV, and other sarbecoviruses. <i>Emerging Microbes and Infections</i> , 2022, 11, 147-157.	3.0	25
52	Was HIV present in 1959?. <i>Nature</i> , 1995, 374, 503-504.	18.7	23
53	Functional properties of the spike glycoprotein of the emerging SARS-CoV-2 variant B.1.1.529. <i>Cell Reports</i> , 2022, 39, 110924.	2.9	20
54	Functional differences among the spike glycoproteins of multiple emerging severe acute respiratory syndrome coronavirus 2 variants of concern. <i>Science</i> , 2021, 24, 103393.	1.9	17

#	ARTICLE	IF	CITATIONS
55	Angiotensin converting enzyme 2 is a novel target of the β -secretase complex. Scientific Reports, 2021, 11, 9803.	1.6	13
56	Prolonged severe acute respiratory syndrome coronavirus 2 persistence, attenuated immunologic response, and viral evolution in a solid organ transplant patient. American Journal of Transplantation, 2022, 22, 649-653.	2.6	9
57	Antibody screening at reduced pH enables preferential selection of potently neutralizing antibodies targeting SARS-CoV-2. AICHE Journal, 2021, 67, e17440.	1.8	4
58	Development and performance of a point-of-care rapid antigen test for detection of SARS-COV-2 variants. Journal of Clinical Virology Plus, 2022, 2, 100080.	0.4	3
59	Ad26.COV2.S boosts antibody and T-cell responses following BNT162b2 vaccination. Emerging Microbes and Infections, 2021, 10, 2220-2222.	3.0	2
60	Paired Heavy and Light Chain Signatures Contribute to Potent SARS-CoV-2 Neutralization in Public Antibody Responses. SSRN Electronic Journal, 0, , .	0.4	1
61	Comments on "An airway organoid-based screen identifies a role for the HIF1 α glycolysis axis in SARS-CoV-2 infection". Journal of Molecular Cell Biology, 2021, , .	1.5	1